HOME >> BIOLOGY >> NEWS
Pittsburgh researchers engineer and successfully test SARS corona vaccine in animal model

PITTSBURGH, Dec. 4 -- Research by scientists at the University of Pittsburgh School of Medicine and the Graduate School of Public Health (GSPH) in collaboration with colleagues at the Centers for Disease Control and Prevention (CDC) in Atlanta has shown that an adenoviral-based vaccine can induce SARS-coronavirus (SARS-CoV)-specific T-cell and virus-neutralizing antibody responses.

The study, which represents the first published work on the development of a SARS vaccine and comes only a few months after the SARS coronavirus was identified and its genome was sequenced, is reported in a fast track research letter in the Dec. 6 issue of The Lancet.

"It is our hope that this research will lead to a protective vaccine against SARS," stated project leader Andrea Gambotto, M.D., from the departments of surgery and medicine, division of infectious diseases and the Molecular Medicine Institute (MMI) at the University of Pittsburgh School of Medicine.

In the study, researchers immunized six rhesus macaques intramuscularly with a combination of three SARS-CoV vectors. Two additional macaques were immunized with the same amount of empty adenoviral vector and served as controls. After 28 days, the animals received a second vaccination. Six weeks after vaccination, T-cells and antibodies against SARS were detected in all six of the immunized animals, but not in either of the control animals. The intensity of the response varied among animals but was generally largest after the booster vaccination, according to the Pittsburgh researchers. Serum samples from the vaccinated animals, but not from the controls, showed strong neutralizing capacity against SARS-CoV.

"From a scientific perspective, several points are important. We obtained the recombinant vaccine by engineering a common cold virus to express the SARS coronavirus antigens. This is a successful strategy that we are exploring for other infectious diseases such as HIV," said Dr. Gambott
'"/>

Contact: Frank Raczkiewicz
RaczkiewiczFA@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
4-Dec-2003


Page: 1 2 3

Related biology news :

1. University of Pittsburgh receives $10 million grant for head and neck cancer
2. University of Pittsburgh medical center among first to implant heart assist device
3. University of Pittsburgh receives NIH funding to develop heart assist device for infants
4. Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon
5. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
6. Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers
7. University of Pittsburgh scientist honored for major accomplishment in cancer research
8. Worlds largest scientific society to hold regional meeting in Pittsburgh
9. University of Pittsburgh named cooperative research center for muscular dystrophy
10. Infectious disease study findings presented by University of Pittsburgh scientists
11. University of Pittsburgh study links gynecological complaint to increased risk for herpes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 20, 2020 , ... NDA ... , a Clinical Operations executive with expertise in clinical trial planning and feasibility, ... as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate ... reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... ... True Terpenes , the leading platform for terpene innovation, research and ... the medical potential of terpenes and the potential entourage effect , where the ... focused on expanding the recently launched line of effects-based terpenes - Terpology by ...
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... R3 Stem ... injections for only $3950. With 50 million stem cells total, patients may choose which ... cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
Breaking Biology Technology:
Cached News: